文献速递生殖医学

口服避孕药与孕激素预处理对多囊卵巢综合征女性IVF结局的影响

Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome.
PubMed 文献 · Hum Reprod · 2016-12-19

该研究为多中心随机试验的嵌套队列二次分析,纳入1508例多囊卵巢综合征女性,比较口服避孕药、孕激素诱导月经与等待自然月经对IVF妊娠及活产率的影响。口服避孕药组新鲜胚胎移植后临床妊娠率和活产率低于自然月经组,冻胚移植后流产率更高;孕激素组结局与自然月经组相似。

要点

  • 口服避孕药诱导月经的新鲜胚胎移植临床妊娠率48.8% vs 自然月经63.6%,RR 0.77(95%CI 0.66-0.89)。
  • 口服避孕药组新鲜胚胎移植活产率36.1% vs 自然月经48.1%,RR 0.75(95%CI 0.61-0.92)。
  • 孕激素诱导月经与自然月经相比,妊娠、流产及活产率相似。

核心结论

  • 口服避孕药用于IVF周期安排与新鲜胚胎移植后较低的妊娠率和活产率相关,而孕激素用于此目的则获得比口服避孕药更高的妊娠率和活产率。
  • 作者认为,在采用GnRH拮抗剂方案进行IVF的多囊卵巢综合征女性中,等待自然月经或使用孕激素诱导月经是比使用口服避孕药更好的选择。
  • 需要进一步随机对照研究来证实这些发现。

研究设计与样本

  • 研究为嵌套队列研究,是一项多中心随机试验(Frefro-PCOS)的二次分析,该试验设计比较新鲜胚胎移植与冻胚移植后的活产率。
  • 2013年6月至2014年5月期间从14个中心共纳入1508名女性。
  • 根据当地研究者的判断,受试者被指示等待自然月经(对照组,n=323),或给予孕激素(P组,n=283)或口服避孕药(OCs组,n=902)以在卵巢刺激开始前诱导月经。
  • 在诱导或自然月经周期的第2或3天启动GnRH拮抗剂方案。

主要发现

  • 新鲜胚胎移植后,口服避孕药诱导月经的女性临床妊娠率低于自然月经女性(48.8% vs 63.6%,相对率RR 0.77,95%CI 0.66-0.89)。
  • 新鲜胚胎移植后,口服避孕药诱导月经的女性活产率低于自然月经女性(36.1% vs 48.1%,RR 0.75,95%CI 0.61-0.92)。
  • 冻胚移植后,口服避孕药诱导月经的女性妊娠率与自然月经女性相似,但流产率更高(27.7% vs 13.0%,RR 2.13,95%CI 1.28-3.52)。
  • 冻胚移植后,口服避孕药诱导月经、孕激素诱导月经和自然月经女性的活产率分别为49.4%、50.7%和60.2%(P=0.06)。
  • 与自然月经相比,孕激素诱导月经与新鲜或冻胚移植后的妊娠率、流产率和活产率相似;多因素logistic回归分析显示口服避孕药诱导月经与较低的活产率相关。

临床怎么用

  • 作者认为,对于多囊卵巢综合征女性,在采用GnRH拮抗剂方案进行IVF卵巢刺激前,等待自然月经或使用孕激素诱导月经是比使用口服避孕药更好的选择。

局限性

  • 月经诱导方法非随机分配,由于研究设计及观察到不同组女性基线特征存在显著差异,选择偏倚可能性很高。
  • 本研究人群平均BMI相对正常,结果对肥胖多囊卵巢综合征女性的适用性需在进一步研究中评估。
  • 需要进一步随机对照研究来证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Do oral contraceptives (OCs) and progestins impact live birth rate of IVF when used for cycle scheduling in women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: OCs used for scheduling IVF cycle were associated with lowered rates of pregnancy and live birth after fresh embryo transfer, whereas progestins used for this purpose yield higher rates of pregnancy and live birth than OCs. WHAT IS KNOWN ALREADY: Due to oligo-menorrhea in PCOS, OCs and progestin are extensively used to schedule the start of an IVF cycle in women with PCOS. Little is known about the effect of such pretreatments on outcomes, especially, the rate of live birth. STUDY DESIGN, SIZE, DURATION: This was a nested cohort study and secondary analysis of a multicenter randomized trial, which was designed to compare live birth rate after fresh embryo transfer vs frozen embryo transfer (FET) in women with PCOS (Frefro-PCOS). A total of 1508 women were enrolled from 14 centers between June 2013 and May 2014. PARTICIPANTS/MATERIALS, SETTING, METHODS: At the discretion of local investigators, subjects were instructed to wait for spontaneous menses (Control group, n = 323), or were prescribed progestins (P group, n = 283) or OCs (OCs group, n = 902) to induce menstruation prior to the start of ovarian stimulation. GnRH antagonist protocol was initiated at Day 2 or 3 of induced or spontaneous menses cycle. The rates of pregnancy, pregnancy loss and live birth after either fresh embryo transfer or FET were compared among these three groups. MAIN RESULTS AND THE ROLE OF CHANCE: With fresh embryo transfer, women with OC-induced menses had lower rates of clinical pregnancy (48.8% vs 63.6%, relative rate (RR): 0.77, 95% CI: 0.66-0.89) and live birth (36.1% vs 48.1%, RR: 0.75, 95% CI: 0.61-0.92) than women with spontaneous menses. With freeze-all and deferred FET, women with OC-induced menses had a similar pregnancy rate but a higher pregnancy loss rate (27.7% vs 13.0%, RR: 2.13, 95% CI: 1.28-3.52) after FET than women with spontaneous menses. The live birth rate after FET in women with OC-induced menses, progestin-induced menses and spontaneous menses was 49.4%, 50.7% and 60.2%, respectively (P = 0.06). Progestin-induced menses was associated with similar rates of pregnancy, pregnancy loss and live birth after transfer of either fresh or frozen embryos compared with spontaneous menses. Multivariate logistic regression analysis showed that OCs used for menses induction was associated with lower rate of live birth. LIMITATIONS, REASONS FOR CAUTION: The methods for menses induction were not assigned randomly, thus selection bias was highly likely because of the study design and significant differences that were observed in the baseline characteristics of the women in the different groups. The mean BMI in this study population was relatively normal; the applicability of this result to obese PCOS women needs to be evaluated in further study. WIDER IMPLICATIONS OF THE FINDINGS: Our results suggest that either waiting for a spontaneous menses or using progestin is a better option than using OCs to induce menses in women with PCOS prior to ovarian stimulation using GnRH antagonist protocol for IVF. Further randomized controlled studies are needed to confirm our findings. STUDY FUNDING/COMPETING INTERESTS: This study was funded by National Basic Research Program of China (973 Program) (2012CB944700), the State Key Program of National Natural Science Foundation of China (81430029), National Natural Science Foundation of China (81471428) and Thousand Talents Program (Drs Legro and Zhang H). Dr Legro reports receiving consulting fees from Euroscreen, Kindex, Bayer and Millendo Pharmaceuticals and research funding from Ferring. Others report no disclosures. TRIAL REGISTRATION NUMBER: Frefro-PCOS was registered at Clinicaltrials.gov: NCT01841528.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Wei D, Shi Y, Li J, et al. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome. Hum Reprod. 2016. PMID: 27999118. doi:10.1093/humrep/dew325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。